Shareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”) issues this corrected notice to clarify the deadline to seek appointment as Lead Plaintiff in the securities class action against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) and other defendants. On March 27, 2025, Scott+Scott filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium (NYSE American: ATNM), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b‑5) on behalf of all persons other than Defendants who purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553. On March 27, 2025, Scott+Scott published a notice which inadvertently stated that the deadline to seek appointment as Lead Plaintiff is May 26, 2025. Pursuant to the March 27, 2025 notice published in connection with the Action, however, under the Private Securities Litigation Report Act of 1995, investors who purchased or otherwise acquired Actinium securities during the Class Period may, no later than May 27, 2025, seek to be appointed as Lead Plaintiff for the Class. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed Class.

As set forth in its March 27, 2025 notice, Scott+Scott filed an action on behalf of its client, Nitin Kohil, and the case is captioned: Kohil v. Actinium Pharmaceuticals, Inc., et al., Case No. 1:25-cv-02553. The complaint is based on an extensive investigation and a careful evaluation of the merits of this case. Additional information about the Action is available here.

LEAD PLAINTIFF DEADLINE ON MAY 27, 2025

Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. Iomab-B is an induction-and-conditioning agent used before bone marrow transplants and has the potential to treat elderly relapsed or refractory acute myeloid leukemia. Actinium evaluated Iomab-B in the pivotal Phase 3 Sierra trial (the “Sierra Trial”), where the drug met the primary endpoint of durable Complete Remission with statistical significance (p<0.0001).

The Class Action alleges that, during the Class Period, Defendants made misleading statements and omissions regarding the Company’s business, financial condition, and prospects. Specifically, Defendants misled the market to believe the data submitted in support of its Biologics License Application (“BLA”) was likely to satisfy the U.S. Food and Drug Administration’s guidelines for acceptance and approval of Actinium’s BLA.

As the truth about Actinium’s business reached the market, the price of Actinium’s stock suffered significant declines, harming investors. For example, on the morning of August 5, 2024, before the market opened, when Actinium issued a press release providing, among other things, a regulatory update on the planned BLA filing and the future plans for Iomab-B in the U.S. Specifically, the press release revealed the Company would need to conduct an additional clinical trial to further support the Company’s BLA filing. On this news, the price of Actinium’s common stock plummeted $3.69, or nearly 60%, to close at $2.48, on unusually high trading volume.

LEAD PLAINTIFF DEADLINE ON MAY 27, 2025

If you purchased Actinium securities during the Class Period and were damaged thereby, you are a member of the “Class” and may be able to seek appointment as lead plaintiff.

If you wish to apply to be lead plaintiff, a motion on your behalf must be filed with the U.S. District Court for the Southern District of New York no later than May 27, 2025. The lead plaintiff is a court-appointed representative for absent class members of the Class. You do not need to seek appointment as lead plaintiff to share in any Class recovery in the Class Action. If you are a Class member and there is a recovery for the Class, you can share in that recovery as an absent Class member.

If you wish to apply to be lead plaintiff, please contact attorney Nicholas Bruno at (888) 398-9312 or at nbruno@scott-scott.com.

What You Can Do?

You may contact an attorney to discuss your rights regarding the appointment of lead plaintiff or your interest in the Class Action. You may retain counsel of your choice to represent you in the Class Action.

About Scott+Scott

Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoing, including securities law and shareholder violations. With more than 100 attorneys in eight offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been repeatedly recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States.

To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit www.scott-scott.com.

This may be considered Attorney Advertising.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250408748438/en/